2023 Guidance and Q3 Earnings

Investor roadmap to end of 2024 Execution Pipeline Phase III and regulatory decisions² • Q2 2023 Q2 and Half-year 2023 results Full-year 2023 upgraded guidance く Therapy Area Strategy R&D priorities Arexvy US KK regulatory approval ☑ Arexvy second Q3 2023 Q3 and Year-to-date 2023 results Arexvy RSV, ≥60 YOA (JP) Arexvy, RSV, 50-59 YoA Q4 2023 Full-year and Q4 2023 results Performance vs BIU 20211 Full-year 2024 guidance Apretude, HIV pre-exposure (EU) Vocabria, HIV treatment (CN) Ojjaara, MOMENTUM, myelofibrosis (US) Jemperli RUBY, 1L DMMR/MSI-H EC³ (US) season data BELLUS Health, Inc. acquisition Capital Allocation completed SCYNEXIS, Inc. exclusive license completed Capital allocation R&D and BD priorities TA priorities Investor Engagement Meet the management, Infectious Diseases GSK 1. June 2021 Investor Update 4. Overall survival population Π ☑ > > Meet the management, HIV ☑ Full-year 2023 dividend declaration KKKKKK HT 2024 • Q1 2024 results • Q2 and Half-year 2024 results • H2 2024 Q3 and Year-to-date 2024 results Full-year and Q4 2024 results Performance vs BIU 20211 • Guidance 2025 • • • • . • • Jemperli: RUBY, 1L DMMR/MSI-H EC³ (EU) Ojjaara: MOMENTUM, myelofibrosis (EU, JP) gepotidacin: EAGLE-1, GC depemokimab: SWIFT-1/2, asthma Blenrep: DREAMM-7, 2L+ MM Jemperli: RUBY (Part 2), 1L EC³ Jemperli: RUBY (Part 1) 1L OS4 EC3 Zejula: FIRST, IL maintenance OC ovarian cancer • Arexvy: RSV, 50-59 YOA (US, EU, JP) • Nucala: CRSwNP (JP) • Nucala: severe asthma (CN) depemokimab: ANCHOR-1/2, CRSWNP Nucala MATINEE, COPD cobolimab: COSTAR, 2L NSCLC Blenrep: DREAMM-8, 2L MM Zejula: ZEAL, 1L maintenance NSCLC linerixibat: GLISTEN, PBC5 Meet the management, Oncology Roadshows Meet the management, Respiratory Medical congresses 2. Includes phase III data readouts and regulatory decisions with the applicable geography denoted in brackets 5. cholestatic pruritus in primary biliary cholangitis Full-year 2024 dividend declaration 3. Endometrial cancer 21

View entire presentation